[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609678":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":285,"collaborators":11,"id":287,"slug":11,"hasResults":288,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":288,"sex":294,"minAge":295,"maxAge":11,"enrollmentInfo":296,"targetDuration":11,"studyType":299,"phases":300,"briefSummary":302,"conditions":303,"keywords":307,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":323},{"fullName":5,"class":6},"SOFIE","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with gastric or esophageal cancer receiving [18F]FAPI-74","EXPERIMENTAL",null,[13],"Drug: [18F]FAPI-74 PET\u002FCT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","[18F]FAPI-74 PET\u002FCT","\\[18F\\]FAPI-74 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with gastric or esophageal cancers.",[9],[21],{"name":22,"affiliation":5,"role":23},"Sherly Mosessian, Ph.D","STUDY_DIRECTOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":11,"email":29},"Alex Osipova","CONTACT","1-800-753-5368","Alex.osipova@sofie.com",{"name":31,"role":27,"phone":28,"phoneExt":11,"email":32},"Bridget Adams","bridget.adams@sofie.com",[34,58,74,90,106,122,139,156,173,189,206,223,236,253,268],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Helios CR Inc.\u002FRadNet","RECRUITING","Cerritos","California","90703","United States",{"type":42,"coordinates":43},"Point",[44,45],-118.06479,33.85835,{"lat":45,"lon":44},[48,52,55],{"name":49,"role":27,"phone":50,"phoneExt":11,"email":51},"Sabrina Mora","562-693-4477","Sabrina.mora@heliosclinical.com",{"name":53,"role":27,"phone":11,"phoneExt":11,"email":54},"Alexis Velasco","alexis.velasco@heliosclinical.com",{"name":56,"role":57,"phone":11,"phoneExt":11,"email":11},"Omkar Marathe, M.D.","PRINCIPAL_INVESTIGATOR",{"facility":59,"status":36,"city":60,"state":38,"zip":61,"country":40,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"City of Hope National Cancer Center","Duarte","91010",{"type":42,"coordinates":63},[64,65],-117.97729,34.13945,{"lat":65,"lon":64},[68,72],{"name":69,"role":27,"phone":70,"phoneExt":11,"email":71},"Miranda Qian","(626) 218-3533","lqian@coh.org",{"name":73,"role":57,"phone":11,"phoneExt":11,"email":11},"Dani Castillo, M.D.",{"facility":75,"status":36,"city":76,"state":38,"zip":77,"country":40,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Hoag Memorial Hospital","Irvine","92618",{"type":42,"coordinates":79},[80,81],-117.82311,33.66946,{"lat":81,"lon":80},[84,88],{"name":85,"role":27,"phone":86,"phoneExt":11,"email":87},"Beth Thomsen","949-557-0285","Beth.thomsen@hoag.org",{"name":89,"role":57,"phone":11,"phoneExt":11,"email":11},"Gary Ulaner, MD",{"facility":91,"status":36,"city":92,"state":38,"zip":93,"country":40,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"UCLA","Los Angeles","90095",{"type":42,"coordinates":95},[96,97],-118.24368,34.05223,{"lat":97,"lon":96},[100,104],{"name":101,"role":27,"phone":102,"phoneExt":11,"email":103},"Steven Stokes","310 206-7436","SStokes@mednet.ucla.edu",{"name":105,"role":57,"phone":11,"phoneExt":11,"email":11},"Mark Girgis, MD",{"facility":107,"status":36,"city":108,"state":38,"zip":109,"country":40,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"Stanford University","Stanford","94305",{"type":42,"coordinates":111},[112,113],-122.16608,37.42411,{"lat":113,"lon":112},[116,120],{"name":117,"role":27,"phone":118,"phoneExt":11,"email":119},"Kavin Tamizhmani","(650)-497-6046","ktamizhm@stanford.edu",{"name":121,"role":57,"phone":11,"phoneExt":11,"email":11},"Matteo Novello, MD",{"facility":123,"status":36,"city":124,"state":125,"zip":126,"country":40,"cosmosGeoPoint":127,"geoPoint":131,"contacts":132},"Moffit Cancer Center","Tampa","Florida","33612",{"type":42,"coordinates":128},[129,130],-82.45843,27.94752,{"lat":130,"lon":129},[133,137],{"name":134,"role":27,"phone":135,"phoneExt":11,"email":136},"Jacqueline Guillermo Adams","813-745-2468","Jacqueline.GuillermoAdams@moffitt.org",{"name":138,"role":57,"phone":11,"phoneExt":11,"email":11},"Ghassan El-Haddad, MD",{"facility":140,"status":36,"city":141,"state":142,"zip":143,"country":40,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"Indiana University Health University Hospital","Indianapolis","Indiana","46202",{"type":42,"coordinates":145},[146,147],-86.15804,39.76838,{"lat":147,"lon":146},[150,154],{"name":151,"role":27,"phone":152,"phoneExt":11,"email":153},"Eric Grubbs","(317) 274-2584","eegrubbs@iu.edu",{"name":155,"role":57,"phone":11,"phoneExt":11,"email":11},"Cindy Yuan, MD PhD",{"facility":157,"status":36,"city":158,"state":159,"zip":160,"country":40,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"Massachusetts General Hospital","Boston","Massachusetts","02114",{"type":42,"coordinates":162},[163,164],-71.05977,42.35843,{"lat":164,"lon":163},[167,171],{"name":168,"role":27,"phone":169,"phoneExt":11,"email":170},"Isabelle Lin","617-643-6837","ilin4@mgh.harvard.edu",{"name":172,"role":57,"phone":11,"phoneExt":11,"email":11},"Shadi Esfahani, MD",{"facility":174,"status":36,"city":175,"state":159,"zip":176,"country":40,"cosmosGeoPoint":177,"geoPoint":181,"contacts":182},"UMass\u002FShields","Worcester","01655",{"type":42,"coordinates":178},[179,180],-71.80229,42.26259,{"lat":180,"lon":179},[183,187],{"name":184,"role":27,"phone":185,"phoneExt":11,"email":186},"Sara Schiller","774-548-1090","Sara.Schiller1@umassmed.edu",{"name":188,"role":57,"phone":11,"phoneExt":11,"email":11},"Elisa Franquet-Elia, MD",{"facility":190,"status":36,"city":191,"state":192,"zip":193,"country":40,"cosmosGeoPoint":194,"geoPoint":198,"contacts":199},"Mayo Clinic Rochester","Rochester","Minnesota","55905",{"type":42,"coordinates":195},[196,197],-92.4699,44.02163,{"lat":197,"lon":196},[200,204],{"name":201,"role":27,"phone":202,"phoneExt":11,"email":203},"Kera Delaney","507-293-2227","delaney.kera@mayo.edu",{"name":205,"role":57,"phone":11,"phoneExt":11,"email":11},"Ajit H Goenka, MD",{"facility":207,"status":208,"city":209,"state":209,"zip":210,"country":40,"cosmosGeoPoint":211,"geoPoint":215,"contacts":216},"Icahn School of Medicine at Mount Sinai","NOT_YET_RECRUITING","New York","10029",{"type":42,"coordinates":212},[213,214],-74.00597,40.71427,{"lat":214,"lon":213},[217,221],{"name":218,"role":27,"phone":219,"phoneExt":11,"email":220},"Ilda Bander","212-241-0763","Ilda.bander@mountsinai.org",{"name":222,"role":57,"phone":11,"phoneExt":11,"email":11},"Sampanna Rayamajhi, MD",{"facility":224,"status":36,"city":209,"state":209,"zip":225,"country":40,"cosmosGeoPoint":226,"geoPoint":228,"contacts":229},"Memorial Sloan Kettering Cancer Center","10065",{"type":42,"coordinates":227},[213,214],{"lat":214,"lon":213},[230,234],{"name":231,"role":27,"phone":232,"phoneExt":11,"email":233},"Jordayna Francois","(646)888-6819","francoij@mskcc.org",{"name":235,"role":57,"phone":11,"phoneExt":11,"email":11},"Aria Razmari, MD",{"facility":237,"status":36,"city":238,"state":239,"zip":240,"country":40,"cosmosGeoPoint":241,"geoPoint":245,"contacts":246},"Cleveland Clinic","Cleveland","Ohio","44194",{"type":42,"coordinates":242},[243,244],-81.69541,41.4995,{"lat":244,"lon":243},[247,251],{"name":248,"role":27,"phone":249,"phoneExt":11,"email":250},"Molly Haberkorn","216-445-6434","HABERKS@ccf.org",{"name":252,"role":57,"phone":11,"phoneExt":11,"email":11},"Nicholas Austin, DO",{"facility":254,"status":36,"city":254,"state":239,"zip":255,"country":40,"cosmosGeoPoint":256,"geoPoint":260,"contacts":261},"Kettering","45429",{"type":42,"coordinates":257},[258,259],-84.16883,39.6895,{"lat":259,"lon":258},[262,266],{"name":263,"role":27,"phone":264,"phoneExt":11,"email":265},"Kathren Garber","937-395-8390","kathren.garber@ketteringhealth.org",{"name":267,"role":57,"phone":11,"phoneExt":11,"email":11},"Arif Sheikh, MD",{"facility":269,"status":36,"city":270,"state":271,"zip":272,"country":40,"cosmosGeoPoint":273,"geoPoint":277,"contacts":278},"University of Pennsylvania, Perelman School of Medicine","Philadelphia","Pennsylvania","19104",{"type":42,"coordinates":274},[275,276],-75.16362,39.95238,{"lat":276,"lon":275},[279,283],{"name":280,"role":27,"phone":281,"phoneExt":11,"email":282},"Erin Schubert","215-573-6569","Erin.schubert@pennmedicine.upenn.edu",{"name":284,"role":57,"phone":11,"phoneExt":11,"email":11},"Mark Sellmyer, MD, PhD",{"type":286,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100609678",false,"NCT07217704","Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.","A Phase 3, Multicenter, Prospective Open-Label Study of the Diagnostic Performance of [¹⁸F]FAPI-74 PET\u002FCT for the Detection of Metastatic Disease in Adults With Gastric or Esophageal Cancer","FAPI-GO","Inclusion Criteria:\n\n* Male and female adults ≥ 18 years.\n* Participants with confirmed gastric, esophageal or gastroesophageal malignancy undergoing staging evaluation for treatment planning.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2.\n* Provided signed, written informed consent prior to any study-related procedures.\n* Participants are required to have a ceCT scan of chest, abdomen and pelvis as per standard clinical practice and practice guidelines either 21 days or less prior to entry or planned within 21 days of \\[¹⁸F\\]FAPI-74 administration.\n* For women who are not postmenopausal (two years of amenorrhea) or surgically sterile (absence of ovaries and\u002For uterus): agreement to use medically accepted, highly effective methods of contraception (e.g., hormonal implants, combined oral contraceptives, vasectomized partner, during the trial intervention period.\n\nExclusion Criteria:\n\n* Unequivocal evidence of metastases at the time of enrollment that would preclude surgery as a treatment option.\n* Known hypersensitivity to \\[¹⁸F\\]FAPI-74.\n* Administration of another investigational diagnostic or therapeutic product within 30 days prior to \\[¹⁸F\\]FAPI-74 administration.\n* Prior administration of a radiopharmaceutical within 10 half-lives of that product from the time of \\[¹⁸F\\]FAPI-74 administration.\n* Previous cancer (except basal cell carcinoma of the skin or in situ carcinoma of the cervix\u002Futerus (participants treated with curative intent and disease free for more than 5 years are permitted).\n* Hepatic function: T. bili \\>1.5X ULN or alk phos, ALT, or AST \\>5X ULN\n* Renal function: GFR \\\u003C 30 mL\u002Fmin\n* Pregnant or currently breast feeding (a negative pregnancy test is required in women of childbearing potential).\n* Inability to undergo the PET\u002FCT scanning procedure.\n* Inflammatory bowel disease (Crohn's disease, ulcerative colitis)\n* Sarcoidosis\n* Treatment, including chemotherapy, radiation, immunotherapy or surgery for curative intent of Gastroesophageal cancers","ALL","18 Years",{"count":297,"type":298},200,"ESTIMATED","INTERVENTIONAL",[301],"PHASE3","This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \\[¹⁸F\\]FAPI-74 PET\u002FCT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junction or esophageal cancer. Following screening, using a standardized administration protocol and dose, participants will undergo \\[¹⁸F\\]FAPI-74 PET\u002FCT screening. SOC procedures and interventions will be captured during 3 months +\u002F-14 days post injection. The primary objective is to evaluate the sensitivity and specificity of such \\[¹⁸F\\]FAPI-74 PET\u002FCT using a composite SOT panel. The maximum expected duration of the trial is approximately 24 months from first patient screening to last patient SOC follow up. The participants will be followed-up for safety for 24 to 72 hours after the dose of \\[¹⁸F\\]FAPI-74 PET\u002FCT.",[304,305,306],"Esophageal Cancer","Gastric Cancer (GC)","Gastroesophageal Junction",[308,309,310,311,312,313],"FAP","Fibroblast Activation Protein","Fibroblast Activation Protein Inhibitor","FAPI","gastroesophageal cancer","PET","2026-06-26",{"date":316,"type":317},"2026-06-30","ACTUAL",{"date":319,"type":317},"2025-11-14",{"date":321,"type":298},"2027-08-30",{"name":5,"class":6},15]